Phase 4 Vasculitis Trial, Recruiting (NCT04300686)

Phase 4 Vasculitis Trial, Recruiting NCT04300686 Sponsor: Shanghai Zhongshan Hospital Condition: Vasculitis

Printed from Voxsanity (voxsanity.com.au) — NCT04300686 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Vasculitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 14 years or older
People with an active condition, shown by a Kerr score of 2 or higher (a measure of disease activity — confirm with trial site)
People with a severe form of the condition, meeting at least one of the following: very high blood pressure (above 180/110 mmHg); three or more affected blood vessels with significant narrowing (more than 70% blocked); or significant reduction in how well the heart or kidneys are functioning, measured by specific clinical scores (confirm with trial site)

Who may not be able to join:

People with severe failure of one or more major organs
People with an active infection, whether recent or long-term, including tuberculosis or hepatitis
People who also have another autoimmune disease, such as lupus, Behcet disease, or IgG4-related disease
People who have been diagnosed with a malignant (cancerous) tumour
People who have had a serious allergic reaction to a medication in the past
People whose condition has relapsed twice in a row even after treatment adjustments have been made

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Lindi Jiang, PhD, Fudan University

Phone: +8615221160538

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04300686

Sponsor: Shanghai Zhongshan Hospital

Phase: Phase 4

Status: Recruiting

Condition: Vasculitis

Trial contact: +8615221160538

More information: https://clinicaltrials.gov/study/NCT04300686

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 14 years or older
People with an active condition, shown by a Kerr score of 2 or higher (a measure of disease activity — confirm with trial site)
People with a severe form of the condition, meeting at least one of the following: very high blood pressure (above 180/110 mmHg); three or more affected blood vessels with significant narrowing (more than 70% blocked); or significant reduction in how well the heart or kidneys are functioning, measured by specific clinical scores (confirm with trial site)

Who may not be able to join:

People with severe failure of one or more major organs
People with an active infection, whether recent or long-term, including tuberculosis or hepatitis
People who also have another autoimmune disease, such as lupus, Behcet disease, or IgG4-related disease
People who have been diagnosed with a malignant (cancerous) tumour
People who have had a serious allergic reaction to a medication in the past
People whose condition has relapsed twice in a row even after treatment adjustments have been made

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Shanghai Zhongshan Hospital

Registry

ClinicalTrials.gov

Start date

1 March 2020

Est. completion

1 May 2022

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease remission at 24 weeks.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov